
Webiomed is a predictive analytics platform that uses artificial intelligence and medical data analysis to improve healthcare. They offer solutions for healthcare executives, doctors, pharmaceutical companies, research organizations, and insurance companies. Their platform analyzes electronic medical records (EMRs) to provide risk stratification, disease prediction, decision support for doctors, and insights for administrative decision-making. Webiomed has received recognition, including being listed in the Russian software registry and obtaining a medical device registration certificate. They have also secured patents and certifications, highlighting their commitment to quality and innovation in the AI healthcare space.

Webiomed is a predictive analytics platform that uses artificial intelligence and medical data analysis to improve healthcare. They offer solutions for healthcare executives, doctors, pharmaceutical companies, research organizations, and insurance companies. Their platform analyzes electronic medical records (EMRs) to provide risk stratification, disease prediction, decision support for doctors, and insights for administrative decision-making. Webiomed has received recognition, including being listed in the Russian software registry and obtaining a medical device registration certificate. They have also secured patents and certifications, highlighting their commitment to quality and innovation in the AI healthcare space.
Product: AI-driven predictive analytics and clinical decision support for de-identified EMR data
Founding year: 2018
Regulatory status: Registered as a medical device in Russia
Known funding: Raised > $1.8M (private), total funding listed $2,070,000
Medical data analysis, risk prediction, clinical decision support
2018
Healthcare / Healthtech / Medical AI
> $1,800,000
Company announced more than $1.8M of private investment in July 2020
Third-party profiles report a Series A as last round; amounts and dates are obfuscated in those profiles
“Mail.ru Cloud Solutions mentioned among investors in third-party profile”